MedTrace Logo

Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

NCT03673384 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-09-17

No results posted yet for this study

Summary

Allergic rhinitis is one of the chronic illnesses. At present, the major treatments for allergic rhinitis are avoiding allergens, medical treatment and surgery. However, inadequate effects, and possible side effects of these treatments are still problems to these patients. Therefore, to find an effective non-medical and non-surgical treatment will be of great help in treating patients with allergic rhinitis.

Infrared-C (far-infrared) ray irradiation is able to promote normal operation of autonomic nervous system, to improve blood circulation and thereby assumed to relieve discomfort symptoms of patients with vascular, specific or non-specific allergic rhinitis. Consequently, infrared-C ray irradiation is expected to be effective for the treatment of allergic rhinitis.

The investigators aimed to probe the adjunct effects of infrared-C ray irradiation in terms of infrared-C hot compress in improving allergy symptoms like sneezing, rhinorrhea, nasal obstruction, nose and conjunctiva itching during a medical treatment for patients with allergic rhinitis. Moreover, the impact of infrared-C irradiation on health and life quality enhancement will also be studied.

Conditions

  • Allergic Rhinitis

Interventions

DEVICE

infrared-C ray irradiation

Infrared-C irradiation by hot compress with a powered heating compress

DEVICE

eye mask

infrared-C irradiation by hot compress with a powered heating eye mask

DRUG

Xyzal Oral Product

used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.

DRUG

Fluticasone Furoate

used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.

Sponsors & Collaborators

  • Buddhist Tzu Chi General Hospital

    collaborator OTHER

  • Solano Semiconductor Technology., LTD.

    collaborator UNKNOWN

  • Nanhua University

    lead OTHER

Principal Investigators

  • Chun-Chih Lin, Professor · Nanhua University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-02
Primary Completion
2017-07-30
Completion
2017-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673384 on ClinicalTrials.gov